Intelligencia AI is a company based in Greece that operates within the Computers and Technology industry, specifically focusing on information technology and services. With a workforce of 51 employees and reported revenue of 11 million USD, the company engages in data analysis and research related to drug development. A notable publication from July 2024 highlights their examination of juvenile arthritis (JIA) in conjunction with Juvenile Arthritis Awareness Month. The document provides insights into the current landscape of clinical development programs for JIA, identifying 14 ongoing programs across various phases, including Phase 1, Phase 2, and Phase 3 trials. The company employs an AI-driven approach to assess the probability of technical and regulatory success in drug development, contributing to the understanding of treatment options for JIA, which primarily include disease-modifying antirheumatic drugs, corticosteroids, nonsteroidal anti-inflammatory drugs, and biologics. This research underscores Intelligencia AI's commitment to leveraging technology in the healthcare sector, particularly in the context of chronic autoimmune diseases.